{
    "@graph": [
        {
            "@id": "gnd:1130592375",
            "sameAs": "Eckermann, Simon"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A883118696",
            "@type": "bibo:Book",
            "P1053": "1 Online-Ressource (XXII, 328 Seiten)",
            "description": "Illustrationen",
            "identifier": [
                "(isbn13)9783319506111",
                "(ppn)883118696",
                "(firstid)GBV:883118696",
                "(isbn13)9783319506135"
            ],
            "publisher": "Springer International Publishing",
            "subject": [
                "(classificationName=ddc)330",
                "(classificationName=loc)HB71-74",
                "Health economics",
                "(classificationName=linseach:mapping)sow",
                "(classificationName=linseach:mapping)oek",
                "(classificationName=ddc)362.1",
                "Electronic books"
            ],
            "title": "Health economics from theory to practice : optimally informing joint decisions of research, reimbursement and regulation with health system budget constraints and community bbjectives",
            "abstract": [
                "5.4 Broader Dangers of Population EVPI in Allocating Research Funding -- 5.5 What VOI Method(s) Enable ENG Optimisation -- 5.5.1 Appropriately Allowing for Within Jurisdiction Decision Contexts Applying the CLT -- 5.6 How Can VOI Methods Inform the Choice Between AN, DT and AT Where Feasible? -- 5.7 Expected Value and Cost of Trials with a Delayed Reimbursement Decision (DT Versus AN) -- 5.8 EVSI where Adopting and Trialing is Feasible -- 5.9 Illustrating Optimising of Joint Optimising Research and Reimbursement Decisions - Early Versus Late External Cephalic Version -- 5.9.1 Comparing AT, AN and DT -- 5.9.2 Distinguishing Between Costs of Adoption, Delay and Reversal -- 5.10 More General Implications for Optimising Joint Research and Reimbursement Decisions -- 5.10.1 VOI Advantages over Frequentist Designs in Enabling Efficient Research Design for Joint Research and Reimbursement Decisions -- 5.11 Conclusion and Discussion of Broader VOI Methods Issues Arising for Decision-Making Within Jurisdiction -- References -- Chapter 6: Globally Optimal Societal Decision Maker Trials -- 6.1 Introduction -- 6.2 Expected Value and Costs Across Jurisdictions for Global Trial Design -- 6.3 Illustrating Methods: Globally Optimal Trial Design (The USA, UK and Australia) -- 6.4 Explicitly Addressing Imperfect Translation in Optimal Global Trial Design -- 6.5 Global Trials for Existing Technology -- 6.6 Conclusion: Optimal Global Trial Design as First Best Solution -- References -- Chapter 7: Value of Information, Pricing Under Uncertainty and Risk Sharing with  Optimal Global Trial Design -- 7.1 Introduction -- 7.2 Pricing Under Uncertainty -- 7.3 Illustrating Threshold Pricing Under Uncertainty -- 7.4 Pricing Under Uncertainty with Adoption in a Global Trial",
                "3.4.1 What Causes Reversal of Treatment Effect with Relative Risk? -- 3.5 Preventing Framing Biases in Evidence Translation -- 3.5.1 Does Relative Risk Consistently Estimate Absolute Risk Difference in Translating Evidence with Alternate Framing of Binary Events? -- 3.5.2 Does the Odds Ratio Allow Consistent Estimation of Absolute Risk Difference in Translating Trial Evidence to Jurisdictions of Interest? -- 3.6 Extrapolating Cost Effectiveness Evidence Beyond Trial Duration for a Jurisdiction of Interest -- References -- Chapter 4: Beyond the Individual: Evaluating Community-Based Health Promotion and Prevention Strategies and Palliative Care Domains of Effect -- 4.1 Introduction -- 4.2 Evaluating Health Promotion and Prevention: Moving Beyond Individual Measures Within Study -- 4.2.1 The Stephanie Alexander Evaluation Case Study -- 4.2.2 Conclusion: Health Promotion and Prevention in Complex Community Settings -- 4.3 Palliative Care -- 4.3.1 Economic Evaluation in Palliative Care -- References -- Part II: Joint Research and Reimbursement Questions, Optimising Local and Global Trial Design and Decision Making Under Uncertainty Within and Across Jurisdictions with Value of Information Methods -- References -- Chapter 5: The Value of Value of Information Methods to Decision-Making: What VOI Measures Enable Optimising Joint Research and Reimbursement Decisions Within a Jurisdiction? -- 5.1 Expected Value of Information Principles and Methods -- 5.2 Taking Occam's Razor to VOI Methods - What Is Necessary and Sufficient to Address Research Questions? -- 5.2.1 Candidate Set 1: Per Patient and Population EVPI -- 5.2.2 Candidate Set 2: Per Patient and Population EVSI -- 5.2.3 Candidate 3: The Expected Value Less Cost or Expected Net Gain (ENG) of a Given Trial -- 5.3 What Is Required to Inform Decision-Making Questions: Optimising ENG or Return on Research",
                "7.5 Circuit Breaker Advantages in Bringing Societal Decision Maker and Manufacturer Interests Closer Together -- 7.5.1 Deeper Implications for Implementation and Practice -- 7.6 Bottom Line for VOI Methods -- References -- Part III: Regulating Strategies and Providers in Practice: The Net Benefit Correspondence Theorem Enabling Robust Comparison of Multiple Strategies, Outcomes and Provider Efficiency in Practice Consistent with Net Benefit Maximisation -- References -- Chapter 8: Best Informing Multiple Strategy Cost Effectiveness Analysis and Societal Decision Making: The Cost Disutility Plane and Expected Net Loss Curves and Frontiers -- 8.1 An Introduction to Multiple Strategy Comparison and Limitations of Fixed Comparator Two-Strategy Presentations and Summary Measures -- 8.2 Overcoming Fixed Comparator Problems - Multiple Strategy Comparison of Costs and Effects with Flexible Axes on the C-DU Plane -- 8.3 Net Loss Statistics, Expected Net Loss Curves and the Expected Net Loss Frontier -- 8.4 The ENL Frontier and EVPI -- 8.5 Best Presentation and CE Summary Measures to Inform Risk-Neutral or Somewhat Risk-Averse Societal Decision Making with Two and More than Two Strategies -- 8.6 Discussion of the CEA Frontier -- 8.7 Conclusion -- References -- Chapter 9: Including Quality of Care in Efficiency Measures: Creating Incentives Consistent with Maximising Net Benefit in Practice -- 9.1 Overview -- 9.2 The Need to Include Quality in Efficiency Measures Consistent with Maximising Net Benefit -- 9.3 The Quality of Care Challenge -- 9.3.1 NBCT Proof -- 9.4 Policy Implications of the NBCT Framework -- 9.5 Further Extensions -- References -- Chapter 10: Multiple Effects Cost-Effectiveness Analysis in Cost-Disutility Space -- 10.1 Introduction -- 10.2 Extending Cost-Effectiveness Analysis on the Cost-Disutility Plane -- 10.2.1 Technical Efficiency Frontier",
                "Foreword -- Text Background and Author Acknowledgement -- References -- Abbreviations -- Contents -- Chapter 1: Introduction -- 1.1 Overview -- 1.2 An Appropriate Underlying Objective Function -- 1.3 Principles for Constrained Optimisation Across Health Promotion, Prevention and Care Settings -- 1.4 Overview of Chapters -- References -- Part I: Principles and Practice for Robust Net Benefit Analysis Informing Optimal Reimbursement (Adoption and Financing) Decisions Across Individual and Community-Focused Programs Using Trial, Model and Network Multiplier Methods -- References -- Chapter 2: Principles and Practice for Trial-Based Health Economic Analysis -- 2.1 Overview -- 2.2 Principles for Robust Health Technology Assessment -- 2.3 Decision Analytic Approaches to Robust Analysis -- 2.4 Why Use Incremental Net Benefit and Not Incremental Cost Effectiveness Ratios -- 2.5 Illustrating Principles Within Study: The LIPID Trial Case Study -- 2.6 Representing Cost Effectiveness Uncertainty -- 2.7 Bootstrapping the CE Distribution -- 2.8 Fieller's Method -- 2.9 Useful Cost Effectiveness Summary Measures from Bivariate Distributions Conditioning on Threshold Values for Effect -- 2.10 How Should Economically Meaningful Threshold Values for Effects Be Estimated? -- 2.11 Conclusion -- 2.12 Discussion - Satisfying Coverage, the Need for Robust Evidence Synthesis, Translation and Extrapolation -- References -- Chapter 3: Avoiding Frankenstein's Monster and Partial Analysis Problems: Robustly Synthesising, Translating and Extrapolating Evidence -- 3.1 Introduction -- 3.2 Setting the Scene: Frankenstein's Monster or the Vampire of Trials -- 3.3 Cost Minimisation and the Absence of Evidence Fallacies -- 3.4 Indirect Comparison and Avoiding Framing Biases with Relative Risk in Evidence Synthesis of Binary Outcomes",
                "10.2.2 Deterministic Analyses -- 10.2.2.1 Threshold Regions Across Effect Values where Strategies are Optimal -- 10.2.3 Summary Measures Under Uncertainty: The Value of Accounting for Joint Uncertainty -- 10.2.3.1 Expected Net Loss (ENL) and ENL Planes -- 10.2.4 Expected Net Loss Contour -- 10.2.4.1 Cost-Effectiveness Acceptability Planes -- 10.3 Multiple Domain Palliative Care Example -- 10.3.1 Methods -- 10.3.1.1 Model Structure -- 10.3.1.2 Parameters -- 10.3.1.3 Analysis -- 10.3.2 Results -- 10.3.2.1 Conventional Analyses -- 10.3.2.2 Comparison in Cost-Disutility Space -- 10.3.2.3 Deterministic Analyses -- 10.3.2.4 Stochastic Analysis -- 10.4 Discussion -- 10.5 Conclusion -- References -- Part IV: The Health Shadow Price and Other Key Political Economy and Policy Issues: Appropriate Threshold Pricing and Policy Application of Methods for Optimising Community Net Benefit with Budget Constraints -- References -- Chapter 11: The Health Shadow Price and Economically Meaningful Threshold Values -- 11.1 Overview -- 11.2 Why Are Economically Meaningful Threshold Values Critical -- 11.3 Historical Threshold Values and Opportunity Costs -- 11.4 Considering Displaced Services as a Threshold: The Straw Man Outside the Room -- 11.5 Distinct Dangers of Using Displaced Service Thresholds Over Time, Whether Assumed or Actual and Applied Inconsistently or Consistently -- 11.6 The Health Shadow Price for Reimbursement (Adoption and Financing) -- 11.6.1 The Health Shadow Price and PBMA as a Pathway to Allocative Efficiency -- 11.7 Health Shadow Prices for Cost Saving Investment Options -- 11.8 Conclusion -- References -- Chapter 12: Policy Implications and Applications Across Health and Aged Care Reform with Baby Boomer Ageing - from Age and Dementia Friendly Communities to Palliative Care -- 12.1 Introduction",
                "12.2 Health-Care Policy for Successful Ageing: Where Should Health and Aged Care Reform Be Heading (The Importance of Dementia and Age-Friendly Community Environments)"
            ],
            "contributor": "Technische Informationsbibliothek (TIB)",
            "creator": "gnd:1130592375",
            "isPartOf": "(collectioncode)ZDB-30-PQE",
            "issued": "2017",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "commercial licence",
            "medium": "rda:termList/RDACarrierType/1018",
            "P60163": "Cham"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "contributor": "http://purl.org/dc/terms/contributor",
        "issued": "http://purl.org/dc/terms/issued",
        "abstract": "http://purl.org/dc/terms/abstract",
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "description": "http://purl.org/dc/elements/1.1/description",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "title": "http://purl.org/dc/elements/1.1/title",
        "license": "http://purl.org/dc/terms/license",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "creator": {
            "@id": "http://purl.org/dc/terms/creator",
            "@type": "@id"
        },
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}